Investment research report for AMED

Table of Contents

Executive Summary
Valuation Analysis
Industry and Competitors Analysis
Financial Analysis
Earnings Call Multi-Year Analysis
Financial Statements Multi Year
Insider Trading Analysis
Management Compensation Benchmark Analysis
Proxy Statement Analysis
News Analysis
Technical Indicators Analysis
Financial Statements Annual
Financial Statements Quarterly
Earnings Call Analysis

Executive Summary

Company Overview

Amedisys, Inc. is a leading provider of home health, hospice, and high-acuity care services in the United States. With over 500 care centers across 38 states, the company offers a range of services, including skilled nursing, physical therapy, and hospice care, to patients in their homes or other care settings.

Financial Performance

Amedisys has demonstrated consistent revenue growth, with net service revenue increasing from $1.96 billion in 2019 to $2.22 billion in 2022. The company has maintained profitability, generating net income of $118.6 million in 2022. Amedisys has a strong financial position, with $405 million in cash and cash equivalents and access to a $5.5 billion revolving credit facility as of December 31, 2022.

Strategic Initiatives

Amedisys has pursued a diversification strategy, expanding into high-acuity care services through acquisitions like Contessa Health in 2021. The company is also focused on value-based care partnerships with health systems and payers, positioning itself for the shift towards more integrated and coordinated care models. Additionally, Amedisys has entered into a definitive agreement to be acquired by UnitedHealth Group, a transaction that could significantly enhance its scale and market position.

Industry Landscape

Amedisys operates in the medical care facilities industry, providing home health, hospice, personal care, and high-acuity care services. The company faces competition from various players, including Acadia Healthcare Company, Addus HomeCare Corporation, Encompass Health Corporation, and The Ensign Group, Inc. However, Amedisys has established a strong nationwide footprint and a focus on home-based care services, which aligns with the trend towards more cost-effective healthcare delivery models.

Back to Table of Contents

Valuation Analysis

PE Ratio

The PE ratio for the company AMED is as follows:
– Low: -168.21140094896515
– Base: -5.831046313673756
– High: 156.54930832161762

PB Ratio

The PB ratio for the company AMED is as follows:
– Low: 1.42305933071124
– Base: 5.729794498234558
– High: 10.036529665757875

Due to the highly unstable financials of the company AMED, we are unable to provide reliable price targets. Therefore, we recommend not holding this stock in your portfolio.

Back to Table of Contents

Industry and Competitors Analysis

AMED (Amedisys, Inc.) and Key Competitors

Based on the information provided, AMED (Amedisys, Inc.) operates in the medical care facilities industry, providing home health, hospice, personal care, and high acuity care services across the United States. Some of its key competitors in this industry include:

  1. ACHC (Acadia Healthcare Company, Inc.): A provider of behavioral healthcare services through inpatient psychiatric hospitals, specialty treatment facilities, residential treatment centers, and outpatient clinics.

  2. ADUS (Addus HomeCare Corporation): Offers personal care, hospice, and home health services.

  3. EHC (Encompass Health Corporation): Provides inpatient rehabilitation and home health and hospice services.

  4. ENSG (The Ensign Group, Inc.): Operates skilled nursing facilities, assisted living facilities, and provides ancillary services like home health and hospice care.

  5. OPCH (Option Care Health, Inc.): Provides home and alternate site infusion services, including anti-infective therapies, home parenteral nutrition, and treatments for chronic inflammatory disorders.

  6. UHS (Universal Health Services, Inc.): Owns and operates acute care hospitals, outpatient facilities, and behavioral health care facilities.

  7. SGRY (Surgery Partners, Inc.): Operates a network of surgical facilities, including ambulatory surgery centers and surgical hospitals, offering various surgical procedures and ancillary services.

  8. EHAB (Enhabit, Inc.): Provides home health and hospice services through the Program of All-Inclusive Care for the Elderly (PACE) approach.

  9. PNTG (The Pennant Group, Inc.): Operates home health and hospice agencies, as well as senior living communities.

  10. INNV (InnovAge Holding Corp.): Manages and provides medical and ancillary services for seniors through the PACE approach.

  11. NHC (National HealthCare Corporation): Operates skilled nursing facilities, assisted living facilities, independent living facilities, home care and hospice agencies, and a behavioral health hospital.

  12. HCSG (Healthcare Services Group, Inc.): Provides housekeeping, laundry, linen, facility maintenance, and dietary services to nursing homes, retirement complexes, rehabilitation centers, and hospitals.

Based on the financial metrics provided, AMED appears to be a mid-sized player in the industry, with a market capitalization of around $3 billion and revenue of over $2 billion. Its profitability ratios, such as gross profit, EBITDA, and net income margins, are generally in line with or slightly below some of its larger competitors like EHC, UHS, and ENSG, suggesting a moderate competitive positioning in the industry.

Back to Table of Contents

Chart of Competitors

"Chart of Competitors"

Back to Table of Contents

Financial Analysis

Financial Strength

The company has maintained a relatively stable current ratio around 1, indicating it has sufficient current assets to cover current liabilities. However, the debt-to-equity ratio has increased over time, reaching around 0.6 in recent years, which is on the higher side. Interest coverage ratios have been healthy, mostly above 5-10x, suggesting the company can comfortably service its debt obligations from operating profits.

Potential for Growth

Revenue growth has been modest, mostly in the low single-digits over the past few years. However, analyst estimates project higher revenue growth rates of around 5-10% annually over the next few years. The company operates in the healthcare services industry, particularly home health, hospice, and personal care, which could benefit from favorable demographic trends like an aging population.

Competitive Advantage

With over 500 care centers across 38 states, Amedisys has established a significant nationwide footprint, which could provide a competitive edge through its scale and network. The company’s focus on home-based care services aligns with the trend towards more cost-effective healthcare delivery models.

Quality of Management

Profitability metrics like return on equity and return on assets have been relatively stable, though not exceptionally high, suggesting reasonably effective management of resources. The company has maintained a consistent dividend payout in recent years, which could signal management’s commitment to shareholder returns.

Shareholder Friendliness

Amedisys does not currently pay dividends, which may be less appealing to income-oriented investors. Share buybacks have been limited, with the weighted average share count remaining relatively flat over time.

Valuation

The company’s price-to-earnings ratio has fluctuated significantly, ranging from around 20x to over 50x in recent years, which could indicate potential volatility in the stock’s valuation. Analyst estimates project earnings growth in the mid-to-high single-digit range over the next few years, which could support further stock price appreciation if these estimates are met.

Overall, Amedisys appears to be a reasonably well-managed company with a solid competitive position in the growing home healthcare market. However, its growth prospects and shareholder returns have been relatively modest, and its valuation could be sensitive to changes in earnings expectations.

Back to Table of Contents

Chart of Key Per Share Metrics

"Chart of Key Per Share Metrics"

Back to Table of Contents

Chart of Absolute Metrics

"Chart of Absolute Metrics"

Back to Table of Contents

Earnings Call Multi-Year Analysis

Amedisys consistently highlights labor shortages, wage inflation, and clinician retention as major challenges impacting operations and margins. The company is focused on recruitment, retention strategies (benefits, bonuses, training), and optimizing staff utilization to manage these headwinds.

Diversification and innovation

Amedisys is diversifying beyond traditional home health and hospice into high-acuity care models like hospital-at-home and SNF-at-home through acquisitions (e.g., Contessa). This expands their total addressable market and positions them for value-based care partnerships.

Quality focus and competitive advantage

The company emphasizes maintaining high-quality care as a key differentiator and competitive advantage, which should benefit them as payers shift towards value-based reimbursement models.

Medicare Advantage opportunity

Amedisys sees significant growth potential in the Medicare Advantage market and is actively pursuing value-based, case rate contracts with MA plans, which could drive margin expansion.

Regulatory uncertainty

Potential reimbursement rate cuts (e.g., proposed home health cuts) and changes in payment models create uncertainty, but Amedisys is actively engaging with policymakers to mitigate adverse impacts.

Strategic M&A

Amedisys has the financial flexibility to pursue strategic acquisitions, particularly in home health and hospice, to drive growth and gain market share from smaller competitors.

Operational execution

Despite near-term challenges, Amedisys has demonstrated the ability to execute well, maintain profitability, and position itself for long-term success in the evolving home-based care landscape.

Overall, Amedisys appears well-positioned for long-term growth, driven by its diversification strategy, quality focus, and ability to navigate industry headwinds through operational excellence and strategic initiatives.

Back to Table of Contents

Financial Statements Multi Year

Revenue Growth and Diversification

Amedisys has shown consistent revenue growth driven by expansion across its home health, hospice, personal care, and high acuity care segments. This diversification helps mitigate risks.

Medicare Dependence

A significant portion (around 75%) of Amedisys’ revenue comes from Medicare, exposing the company to changes in government reimbursement policies and regulations.

While revenue has grown, profitability has been impacted by factors like the COVID-19 pandemic, staffing shortages, and reimbursement pressures. However, the company has maintained overall profitability.

Acquisitions and Strategic Moves

Amedisys has pursued an acquisition strategy to expand its services, geographic footprint, and capabilities, including the proposed merger with UnitedHealth Group, which represents a potentially transformative event.

Financial Position

The company has maintained a strong liquidity position, with healthy cash flows from operations and access to credit facilities, providing financial flexibility for growth initiatives and acquisitions.

Operational Challenges

Staffing shortages, wage inflation, and potential changes in patient mix and reimbursement models could impact Amedisys’ ability to control costs and maintain profitability.

Quality and Regulatory Compliance

Amedisys has focused on maintaining high quality scores and regulatory compliance, but remains subject to government audits and potential changes in regulations.

In summary, Amedisys has demonstrated resilience and growth potential, but its heavy reliance on Medicare, operational challenges, and the successful completion of the UnitedHealth Group merger are key factors for long-term investors to consider.

Back to Table of Contents

Insider Trading Analysis

Long-Term Patterns

The CEO, Paul B.K. Kusserow, has consistently been awarded and received a significant number of shares over the years, indicating he holds a large ownership stake in the company. This suggests he is highly incentivized to drive the company’s long-term performance.

Several other executives, including the CFO and other senior leaders, have also received substantial equity awards over time, aligning their interests with shareholders.

There have been some instances of executives selling shares, but the overall trend appears to be one of accumulation rather than significant liquidation of positions.

Recent Patterns

In the most recent 2 years, there have been a number of equity grants to executives, including the CEO, CFO, and other senior leaders. This indicates the company continues to use equity compensation to incentivize and retain key talent.

The number of shares owned by the CEO and other top executives has generally increased over this period through these equity awards.

There have been some isolated instances of executives selling small portions of their holdings, but the overall trend remains one of increasing ownership.

Implications

The long-term and recent insider trading patterns suggest the company’s leadership team is highly aligned with shareholders and focused on driving long-term value creation.

The substantial equity ownership by the CEO and other executives provides strong incentives for them to make decisions that will benefit the company and its shareholders over the long run.

While there have been some sales, the limited nature of these transactions indicates the executives remain confident in the company’s prospects and are not signaling any major concerns.

Overall, the insider trading data paints a picture of a leadership team that is heavily invested in the long-term success of Amedisys, both financially and strategically. This should be reassuring for long-term investors.

Back to Table of Contents

Management Compensation Benchmark Analysis

Executive Compensation Structure at AMED

Based on the information provided, the key insights for a long-term investor in AMED are:

  1. Executive compensation at AMED appears to be structured in a way that aligns with creating long-term shareholder value. The base salary portion of total compensation for the executives is relatively low, ranging from around 10-20% on average. The majority of compensation comes from stock awards and incentive plan compensation, which incentivizes the executives to focus on long-term performance and shareholder returns.

  2. Compared to the other companies examined (ACHC and ADUS), AMED’s executives have a lower base salary portion of total compensation. The average base salary percentage for AMED executives is 33.31%, lower than the 45.22% for ADUS and 22.66% for ACHC. This suggests AMED’s compensation structure is more heavily weighted towards variable, performance-based pay.

  3. Over the years, AMED has maintained a consistent approach to executive compensation, with the base salary portion remaining relatively low. This indicates a long-term focus on aligning executive interests with those of shareholders.

  4. The high percentage of stock awards and incentive plan compensation for AMED’s executives suggests they are incentivized to drive the company’s long-term growth and profitability, which should benefit shareholders over the long run.

Comparison to Benchmarked Companies

In summary, the executive compensation structure at AMED appears to be well-designed to incentivize the leadership team to create long-term shareholder value, which is a positive sign for long-term investors. The company’s approach to executive pay is more shareholder-friendly compared to the benchmarked companies, ACHC and ADUS.

Back to Table of Contents

Proxy Statement Analysis

Executive Compensation Analysis

The following analysis is based on the latest proxy statement of AMED. Based on the information provided in the DEFA14A filing, I do not have enough confidence to definitively state whether the executives at this company are compensated in a way that aligns with creating long-term shareholder value. The filing primarily focuses on disclosures related to the financial analysis and valuation of the company, as well as addressing potential conflicts of interest and shareholder lawsuits.

While the filing suggests that the company and its financial advisor have taken steps to provide a thorough and well-supported valuation analysis, and have addressed transparency concerns raised by shareholders, it does not provide specific details on the executive compensation structure or how it is tied to long-term performance metrics.

To assess the alignment of executive compensation with long-term shareholder value creation, I would need additional information such as:

  1. Details on the components of executive compensation packages (base salary, short-term incentives, long-term incentives, etc.)
  2. Performance metrics and targets used for incentive compensation, and how they relate to long-term value creation
  3. Vesting periods and holding requirements for equity-based compensation
  4. Clawback policies or other mechanisms to align executive interests with long-term performance
  5. Peer group comparisons and benchmarking of compensation practices

Without these specific details on the executive compensation program, it is difficult to confidently assess whether the incentives are structured in a way that promotes long-term value creation for shareholders.

Back to Table of Contents

News Analysis

Positive Factors

Amedisys has been consistently beating earnings estimates in recent quarters, indicating strong financial performance. The company has been expanding its hospice and home health business through strategic acquisitions like AseraCare Hospice, Asana Hospice, and acquiring home health assets in various regions. This expansion should drive future growth.

The aging population and increasing demand for home healthcare services provide a favorable demographic tailwind for Amedisys. The company has been authorizing share repurchase programs, which could enhance shareholder value. Amedisys has been forming joint ventures and partnerships to expand its at-home care offerings and services.

Potential Concerns

Amedisys has faced margin pressure in some quarters due to higher costs. There have been some executive leadership changes, including CEO departures, which could create uncertainty. The company has had to update its guidance lower in certain quarters due to challenges like reimbursement rate changes or cost pressures. Amedisys faces intense competition in the home healthcare industry.

Overall, the general sentiment seems positive, with Amedisys consistently delivering solid financial results, expanding its business through strategic moves, and benefiting from favorable industry trends. However, investors should monitor any potential headwinds like cost pressures, regulatory changes, or competitive threats that could impact future performance.

Back to Table of Contents

Technical Indicators Analysis

Next Week Trading

The recent price action and technical indicators suggest a neutral to slightly bearish outlook for the next week. The TEMA (Triple Exponential Moving Average) has been declining, indicating a potential short-term downward trend. The RSI (Relative Strength Index) is in the neutral range, not signaling overbought or oversold conditions. The short-term SMA (Simple Moving Average) of 20 days is also declining, further confirming the neutral to slightly bearish sentiment.

Resistance and Support Levels

The current price is trading around the 50-day SMA, which could act as a support level. The 200-day SMA is at a higher level, suggesting a potential resistance zone. Traders should monitor these moving averages for potential support and resistance areas.

Short-Term Investor

For a short-term investor, the current technical indicators suggest a cautious approach. The declining TEMA and RSI in the neutral range indicate a lack of strong momentum, which could lead to a consolidation or a minor pullback in the near term. Short-term investors may consider waiting for a clearer trend to emerge before taking a position.

Long-Term Investor

From a long-term perspective, the technical indicators appear relatively stable. The 200-day SMA is still above the current price, indicating an overall upward trend. The ADX (Average Directional Index) is in the 30-40 range, suggesting a moderately strong trend. Long-term investors may view the current price level as a potential entry point, as the long-term outlook remains positive.

In summary, the technical indicators suggest a neutral to slightly bearish outlook for the next week, with potential support and resistance levels to monitor. Short-term investors may want to exercise caution, while long-term investors could consider the current price level as a potential entry point, given the overall positive long-term trend.

Back to Table of Contents

Chart of Valuation History

"Chart of Valuation History"

Back to Table of Contents

Financial Statements Annual

Financial Statements Annual 2024 Q2

Proposed Merger with UnitedHealth Group

The proposed merger with UnitedHealth Group is subject to several closing conditions, including government approvals, that may not be satisfied or completed within the expected timeframe, if at all. There is no assurance the merger will be completed even though shareholders have approved it.

The pending merger creates various uncertainties that could disrupt Amedisys’ operations and make it more difficult to maintain relationships with employees, customers, and other business partners. Amedisys may have to pay significant termination fees to UnitedHealth Group under certain circumstances, which could affect the decisions of a third-party considering an alternative acquisition proposal.

Reimbursement Changes

Changes to Medicare and Medicaid reimbursement could have a material adverse effect on Amedisys’ business and financial results. Future cost containment initiatives by private payers may limit Amedisys’ future revenue and profitability. Possible changes in patient case mix, payor mix, and payment methodologies could materially impact Amedisys’ business and financial performance.

Managed Care Contracts

Amedisys’ failure to negotiate or maintain favorable managed care contracts could adversely affect its business. Quality reporting requirements and value-based purchasing programs may negatively impact Medicare reimbursement for Amedisys.

Economic Environment

An economic downturn or state budget pressures could result in reductions in government program payments and covered services, negatively impacting Amedisys.

Staffing Challenges

Staffing shortages and wage inflation could materially impact Amedisys’ ability to attract and retain qualified personnel, increasing operating costs.

In summary, the key risks relate to the proposed merger, reimbursement changes, managed care contract challenges, staffing pressures, and the overall economic environment – all of which could significantly impact Amedisys’ business and financial performance going forward.

Financial Statements Annual 2023 Q2

Consistent Revenue and Profitability

Amedisys has maintained a strong financial performance, with net service revenue growing from $2.07 billion in 2020 to $2.22 billion in 2022. The company has also been consistently profitable, generating net income of $118.6 million in 2022.

Diversified Business Segments

Amedisys operates four main business segments – home health, hospice, personal care, and high acuity care. This diversification helps mitigate risks and provides growth opportunities across different healthcare services.

Reliance on Medicare

Approximately 74-75% of Amedisys’ consolidated net service revenue comes from Medicare, making the company highly dependent on government reimbursement policies and regulations.

Acquisitions and Expansion

Amedisys has grown through strategic acquisitions, such as the purchase of Contessa Health in 2021 and the acquisitions of Evolution Health and AssistedCare in 2022. These acquisitions have expanded the company’s geographic footprint and service offerings.

Operational Challenges

The company has faced some operational challenges, including the impact of the COVID-19 pandemic, staffing shortages, and reimbursement pressures. These factors have contributed to a decline in operating income from $251.9 million in 2021 to $180.8 million in 2022.

Strong Cash Flows and Liquidity

Amedisys has maintained a healthy cash position, with $405 million in cash and cash equivalents as of December 31, 2022. The company’s cash flow from operations was $133.3 million in 2022, providing financial flexibility.

Debt Management

Amedisys has managed its debt effectively, with a consolidated leverage ratio of 1.7 as of December 31, 2022. The company’s Second Amended Credit Agreement provides access to a $5.5 billion revolving credit facility, which can be used for strategic initiatives and acquisitions.

Quality and Regulatory Compliance

Amedisys has maintained a strong focus on quality of care, with 99% of its home health care centers achieving a 4-star or 5-star quality of patient care rating. However, the company remains subject to various government regulations and audits, which can impact its financial performance.

Overall, Amedisys has demonstrated resilience and adaptability in navigating the challenges of the healthcare industry, while continuing to grow and diversify its business segments to drive long-term value for its shareholders.

Financial Statements Annual 2022 Q2

Diversified Revenue Streams

Amedisys has four main business segments – home health, hospice, personal care, and high acuity care. Medicare remains the largest payor, accounting for 75% of total revenue in 2021, 2020, and 2019.

Consistent Growth

Amedisys has grown its business through acquisitions and organic expansion, increasing net service revenue from $19.6 billion in 2019 to $22.1 billion in 2021, a 13% increase over the 3-year period.

Profitability and Margins

Operating income increased from $177.5 million in 2019 to $251.9 million in 2021, a 42% increase. The operating income margin improved from 9.1% in 2019 to 11.4% in 2021.

Acquisitions and Integration

Amedisys made several acquisitions during the period, including Contessa Health in 2021, which expanded its high acuity care capabilities. The company has been able to successfully integrate these acquisitions.

Regulatory and Reimbursement Changes

Amedisys has navigated changes in Medicare reimbursement, including the implementation of the Patient-Driven Groupings Model (PDGM) in 2020 and the suspension of sequestration cuts in 2020-2021, which impacted its financial performance.

Liquidity and Capital Structure

Amedisys maintains a strong liquidity position, with $427 million in cash and $5.2 billion in available credit facility as of December 31, 2021. The company has also been active in the debt and equity markets to fund acquisitions and growth initiatives.

Focus on Quality and Operational Excellence

Amedisys has maintained high quality scores, with 95% of its home health care centers rated at 4 or 5 stars for quality of patient care. The company continues to invest in technology, workforce optimization, and other initiatives to drive operational efficiency.

Overall, Amedisys has demonstrated consistent growth, profitability, and the ability to adapt to industry changes through strategic acquisitions, operational improvements, and a strong financial position.

Back to Table of Contents

Financial Statements Quarterly

Financial Statements Quarterly 2024 Q2

Revenue Growth

Amedisys reported a 2.7% increase in net service revenue to $571.4 million, driven by volume growth in the home health segment and rate increases across the business.

Profitability

Operating income decreased 26.2% to $52.3 million, primarily due to a $20.7 million increase in merger-related expenses related to the proposed acquisition by UnitedHealth Group. Excluding these one-time costs, operating income would have increased.

Segment Performance

  • Home Health: Operating income increased 8.4% to $60.8 million, driven by volume growth, rate increases, and operational improvements.
  • Hospice: Operating income increased 7.8% to $46.9 million, benefiting from the October 2023 rate increase and cost savings initiatives.
  • High Acuity Care: Operating loss increased to $6.2 million, but the segment saw growth in home recovery care services.

Cash Flow and Liquidity

Operating cash flow decreased $32.5 million to a use of $6.5 million, primarily due to delays in billing and collecting accounts receivable following a cybersecurity incident at Change Healthcare, Amedisys’ claims clearinghouse. However, Amedisys maintains a strong liquidity position with $120.7 million in cash and $514.2 million in available borrowing capacity.

Proposed Merger

Amedisys continues to work towards completing its proposed $101 per share acquisition by UnitedHealth Group, which is expected to close in 2024 subject to shareholder and regulatory approvals.

In summary, Amedisys delivered solid revenue growth and profitability in Q1 2024, with the home health and hospice segments performing well. However, the company faced temporary operational disruptions and higher merger-related expenses, which impacted overall profitability. The proposed acquisition by UnitedHealth Group remains on track.

Financial Statements Quarterly 2024 Q1

Revenue and Profitability

The company has a high reliance on Medicare revenue, which accounts for around 73% of total net service revenue. This exposes the company to risks related to changes in Medicare reimbursement policies.

The company has seen a 5% increase in net service revenue year-over-year, driven by growth in the home health and hospice segments. This indicates the company is able to grow its core business.

Operating income decreased by $12 million year-over-year, primarily due to higher merger-related expenses, incentive compensation costs, and the impact of the return of sequestration. Excluding these items, operating income increased by $32 million, suggesting the underlying business performance is improving.

The company’s net income margin decreased from 5.2% to 1.8% year-over-year, mainly due to the $106 million merger termination fee. Excluding this one-time item, the net income margin would have been around 4.5%, which is a more sustainable level.

Liquidity and Capital Structure

The company has a strong liquidity position, with $781 million in cash and cash equivalents and $5.17 billion in available borrowing capacity under its revolving credit facility as of September 30, 2023.

The company’s days revenue outstanding increased from 461 days at the end of 2022 to 498 days as of September 30, 2023, indicating some delays in billing and collections, which could be a short-term issue.

The company’s leverage ratio of 2.5x as of September 30, 2023, is within its debt covenants, providing financial flexibility.

Strategic Developments

The proposed merger with UnitedHealth Group is a significant event that, if completed, would transform the company’s scale and market position. However, the merger is subject to various closing conditions and regulatory approvals, which introduces uncertainty.

The divestiture of the personal care business simplifies the company’s operations and allows it to focus on its core home health, hospice, and high acuity care segments.

Overall, the company appears to be navigating the current operating environment well, with a strong financial position and improving underlying business performance, despite some near-term headwinds. The proposed merger with UnitedHealth Group represents a potentially transformative event, but its successful completion remains subject to various conditions.

Financial Statements Quarterly 2023 Q4

Revenue and Profitability

Total net service revenue was $556.2 million, with Medicare revenue accounting for 74% of total revenue. Gross profit was $244.6 million, with a gross profit margin of 43.98%. Operating income was $42.2 million, with an operating income margin of 7.59%. Net income was $26.0 million, with a net income margin of 4.67%.

Liquidity and Capital Structure

Cash and cash equivalents were $78.1 million. Total assets were $2,027.4 million, with goodwill and intangible assets of $1,348.3 million. Total liabilities were $933.9 million, including $428.7 million in long-term debt. Total stockholders’ equity was $1,039.9 million.

Cash Flows

Net cash used in operating activities was $9.8 million. Net cash used in investing activities was $1.0 million, primarily for acquisitions. Net cash used in financing activities was $6.3 million. Free cash flow (operating cash flow less capital expenditures) was negative $11.0 million.

Segment Performance

Home Health segment revenue was $349.8 million, with an operating income of $42.2 million. Hospice segment revenue was $199.2 million, with an operating income of $51.8 million. Personal Care segment revenue was $0 million, as the business was divested on March 31, 2023. High Acuity Care segment revenue was $40.0 million, with an operating loss of $6.3 million.

Other Highlights

On June 26, 2023, Amedisys entered into a merger agreement with UnitedHealth Group, under which Amedisys will become a wholly-owned subsidiary of UnitedHealth Group. The company divested its personal care business on March 31, 2023, for net proceeds of $47.8 million.

Overall, Amedisys’ financial performance was mixed, with strong profitability in the Home Health and Hospice segments offset by losses in the High Acuity Care segment. The pending merger with UnitedHealth Group represents a significant strategic development for the company.

Financial Statements Quarterly 2023 Q3

Revenue and Profitability

Net service revenue increased by $11 million (2%) to $552.97 million compared to the prior year period. Gross profit increased by $5.5 million (2.2%) to $255.51 million, with the gross profit margin at 46.2%. Operating income decreased by $10 million (21%) to $37.8 million, with the operating income margin declining to 6.8%. Net income declined by $47.5 million to a loss of $80.28 million, with the net income margin at -14.5%. Earnings per share (EPS) declined from $0.97 to a loss of $2.46 per share.

Segment Performance

The Home Health segment revenue increased by $76 million (2.3%), but operating income declined by $10.3 million (15.5%). The Hospice segment revenue was flat, but operating income increased by $8.7 million (25%). The Personal Care segment revenue increased by $10 million (7.1%), and operating income improved by $0.7 million. The High Acuity Care segment revenue increased by $22 million, but the operating loss widened by $10 million.

Cash Flows and Liquidity

Cash provided by operating activities declined by $226 million to $60.8 million. Cash and cash equivalents increased by $42.1 million to $111.2 million. Total debt decreased by $52 million to $486.8 million, with net debt of $391.4 million.

Other Highlights

The company divested its personal care business on March 31, 2023, receiving net proceeds of $478 million. Amedisys entered into a definitive agreement to be acquired by Option Care Health in a $106 million deal.

Overall, the financial results show a decline in profitability and cash flows, with the company’s high acuity care segment continuing to underperform. The divestiture of the personal care business and the proposed merger with Option Care Health represent significant strategic developments for the company.

Back to Table of Contents

Earnings Call Analysis

Earnings Call Analysis 2023 Q1

Labor Shortage and Capacity Constraints

Amedisys is focused on recruiting, retaining, and developing its clinical staff to ensure it has the capacity to meet growing demand for its services. Labor shortage and capacity constraints are major challenges for the company.

Shift in Payer Mix

Medicare Advantage is growing faster than fee-for-service Medicare. Amedisys is being selective in its Medicare Advantage partnerships, focusing on those that recognize the need for fair reimbursement rates.

Clinical Optimization and Automation

Amedisys is working to remove administrative burdens from its care center staff to allow them to focus on patient care. This is expected to drive $20 million in cost savings in 2023.

Contessa High-Acuity Segment

While behind original plans, Contessa is growing and Amedisys sees significant potential in this business, including a new palliative care partnership with Blue Cross Blue Shield of Tennessee.

Guidance is Conservative

Amedisys has learned from past experiences and is providing more realistic guidance, factoring in significant headwinds like labor costs and incentive compensation. The company seems confident it can overcome these challenges.

M&A Pipeline is Robust

Amedisys has ample financial flexibility and is actively pursuing acquisitions, particularly in home health and hospice, to drive future growth.

Overall, Amedisys is navigating a challenging environment but appears to have a clear strategic plan focused on people, growth, optimization, and its high-acuity segment. The company’s conservative guidance and focus on execution are positive signs for long-term investors.

Earnings Call Analysis 2022 Q4

Innovative Payer Contracts

Amedisys has signed an innovative case rate contract with CVS/Aetna, a large Medicare Advantage plan. This allows Amedisys to provide optimal care and be compensated based on quality metrics like rehospitalization rates. Amedisys is pursuing similar value-based contracts with other payers.

Hospice Stabilization

After seeing challenges in hospice admissions and length of stay, Amedisys is seeing stabilization with ADC growth for two quarters in a row. Discharge rates and median length of stay are normalizing.

High Acuity Growth

Amedisys’ high acuity segment, including hospital at home and SNF at home, saw 25% growth in admissions quarter-over-quarter. Amedisys is investing in integrating nursing functions to improve capacity.

Labor Constraints

Amedisys is facing labor challenges across home health and hospice, impacting volume and costs. The company is focused on enhancing benefits and recruiting to improve clinician retention and capacity.

Reimbursement Uncertainty

Amedisys is awaiting the CMS home health final rule for 2023, which could include proposed behavioral adjustment cuts. The company is working with Congress to mitigate any potential cuts.

Long-Term Optimism

Despite near-term headwinds, Amedisys remains optimistic about the long-term value proposition of its business lines. The company sees significant growth opportunities through innovative payer contracts, high acuity expansion, and market share gains in fee-for-service home health.

Overall, Amedisys is positioning itself for long-term success through strategic partnerships, operational improvements, and a focus on quality care, despite facing some short-term challenges.

Earnings Call Analysis 2022 Q3

Utilization Challenges

Amedisys is seeing softness in utilization of home health services, particularly in the Medicare fee-for-service population. This is partly attributed to the rise in telehealth, where patients are not getting the same level of in-person assessments that could identify the need for home health.

Medicare Advantage Opportunity

Amedisys sees significant growth potential in the Medicare Advantage market, which now accounts for 53% of Medicare beneficiaries. The company is working to shift more of its business to value-based, case rate contracts with MA plans to unlock additional capacity and margin expansion.

Proposed CMS Rate Cut

The proposed 4.2% cut to home health reimbursement rates for 2023 is a major concern. Amedisys strongly disagrees with CMS’ methodology and is working with industry groups and Congress to try to pause or mitigate the cuts.

Cost Management

Amedisys has been proactive in identifying opportunities to centralize functions and automate processes to offset wage inflation and potential reimbursement cuts. This could yield $15-30 million in savings.

Hospice Performance

After facing elevated discharge rates earlier in the year, Amedisys is seeing Hospice admissions and average daily census start to improve sequentially, which should drive better performance in the second half.

Contessa Integration

The integration of Contessa’s high-acuity care services into Amedisys’ home health operations is progressing, though volume growth has been slower than expected due to delays in closing new partnerships.

Overall, Amedisys is navigating a challenging environment but remains focused on quality, cost management, and strategic initiatives to position the company for long-term growth, despite the near-term headwinds from proposed reimbursement cuts.

Earnings Call Analysis 2022 Q2

Amedisys is navigating a challenging operating environment, with labor shortages and inflationary pressures impacting the business. However, the company has been able to execute well and maintain profitability.

Optimizing Clinical Staffing

The company is focused on retaining and optimizing its clinical staff, including increasing utilization of LPNs and PTAs, to manage labor costs. Initiatives like the Connect RN minority acquisition are aimed at improving staffing flexibility.

Targeting Market Share Gains

Amedisys sees opportunities to gain market share from smaller, less operationally sound competitors that are struggling in the current environment. The company is actively targeting accounts where referral patterns may be shifting.

Regulatory Landscape

On the regulatory front, Amedisys is cautiously optimistic about the proposed hospice payment update, but remains vigilant about potential behavioral adjustments that could impact home health reimbursement. The company is engaged with policymakers on these issues.

Contessa High-Acuity Care Segment

The company’s Contessa high-acuity care segment is still ramping up, with some delays in revenue ramp-up. However, Amedisys sees significant long-term potential in value-based care partnerships, including the launch of a risk-based palliative care program.

Mergers and Acquisitions

Amedisys is actively pursuing M&A opportunities, having closed two home health acquisitions so far in 2022. The company believes it can capitalize on market share gains from smaller, less operationally sound competitors.

Overall, Amedisys is navigating a challenging environment but remains focused on optimizing its operations, pursuing strategic growth opportunities, and advocating for favorable regulatory policies – all with the goal of delivering long-term value for shareholders.

Earnings Call Analysis 2022 Q1

Quality and Human Capital are Top Priorities

Amedisys emphasizes maintaining high quality care and investing heavily in recruitment, retention, and training of clinical staff. This focus on quality and people is seen as a competitive advantage.

Diversification and Innovation

Amedisys is expanding beyond just home health and hospice, acquiring Contessa to enter hospital-at-home, SNF-at-home, and capitated palliative care models. This diversification and innovation is aimed at differentiating the company.

Labor Challenges Remain a Key Issue

Amedisys is facing significant labor shortages and wage inflation, which are impacting margins. The company is focused on workforce optimization, technology, and partnerships to address these challenges.

Hospice Length of Stay Volatility

Hospice admissions and length of stay have been unpredictable during the pandemic, creating uncertainty around this segment’s performance. Amedisys is closely monitoring this trend.

Managed Care Transition

Some Medicare Advantage plans are moving away from PDGM-based reimbursement to per-visit arrangements, which could create short-term headwinds but also opportunities for Amedisys to leverage its quality and risk-bearing capabilities.

Guidance and Outlook

Amedisys provided detailed 2022 guidance, highlighting the impact of labor costs, incentive compensation, and investments in Contessa. The company sees 2022 as a “setup year” for stronger performance in 2023.

Overall, the key themes are Amedisys’ focus on quality, innovation, and human capital management to navigate the current challenges and position the company for long-term success in the evolving home-based care landscape.

Earnings Call Analysis 2021 Q4

Amedisys has been able to effectively navigate the turbulent operating environment caused by COVID-19, demonstrating strong execution and adaptability. They have focused on controllable factors like reducing clinical turnover, accelerating recruiting, and driving quality improvements.

Diversified Business Model

The company’s diversified business model, including home health, hospice, personal care, and the new high acuity care segment (Contessa), provides opportunities for growth and innovation in home-based care. Contessa’s partnerships with health systems are progressing well.

Labor Challenges

Labor challenges, including increased clinician quarantines and wage pressures, have impacted Amedisys’ financial performance, but the company is taking proactive measures to retain and recruit staff through initiatives like flexible scheduling and retention bonuses.

Long-term Tailwinds and Positioning

The long-term demographic and regulatory tailwinds for home-based care remain intact, with Amedisys well-positioned to capitalize on these trends through organic growth and strategic acquisitions. However, the near-term operating environment remains fluid and uncertain.

Vaccine Mandate Impact

Amedisys is closely monitoring the potential impact of a vaccine mandate on its workforce and is taking steps to mitigate any disruptions. The company’s vaccination rate among employees is currently around 67%.

2022 Outlook

The company is cautiously optimistic about its ability to grow EBITDA in 2022, though current Street consensus may not fully reflect the ongoing impact of COVID-19 and labor dynamics. Amedisys will provide more clarity on its 2022 outlook as trends evolve.

Overall, Amedisys appears to be navigating the near-term challenges effectively while maintaining a long-term focus on growth and innovation in the home-based care market. The company’s diversified business model and strong financial position provide a solid foundation for future success.

Earnings Call Analysis 2021 Q3

Hospice business challenges

Amedisys is facing lingering impacts of COVID-19 on its hospice business, including decline in senior living facility occupancy, shorter patient lengths of stay, and higher hospice business development (BD) staff turnover. This has delayed their ability to achieve their hospice growth targets.

Hospice turnaround strategy

Amedisys is implementing a turnaround strategy for hospice, focused on hiring more BD staff, retaining existing BD staff, and improving productivity through tools like Medalogix. They are confident this will drive improved hospice growth in the second half of 2021 and into 2022.

Home health strength

Amedisys’ home health business has been performing very strongly, with 20% admissions growth in Q2 2021. They have been able to improve margins through clinical staffing mix and utilization improvements.

Contessa acquisition

The acquisition of Contessa, a hospital-at-home and SNF-at-home provider, expands Amedisys’ total addressable market and capabilities, though it will have a near-term EBITDA drag as they invest in the business.

Conservative guidance

Amedisys has reduced its 2021 guidance ranges due to the lingering hospice challenges and uncertainty around COVID-19 impacts. However, they remain confident in their long-term growth prospects.

Labor challenges

Amedisys is facing some labor challenges, including hospice BD staff turnover and pockets of nursing recruitment difficulties in certain markets. They are focused on retention and recruitment strategies to address these.

Overall, the key message is that Amedisys has a strong core business, but is navigating near-term hospice headwinds that are impacting their growth. Their long-term strategy remains intact, and they are taking actions to address the current challenges.

Back to Table of Contents

The information provided on this blog is for informational purposes only and should not be considered as financial advice. You should consult with a qualified financial professional before making any investment decisions. Past performance is not indicative of future results. Investing involves risk, including the potential loss of principal.